See also this year's filing and all EDGAR filings for this company.
PDF Report 0001114220_2018_Keryx_Biopharmaceuticals_INC.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001114220, Keryx Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 141,566,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 3,208,000 |
| 2 | PropertyPlantAndEquipmentNet | 4,521,000 |
| 3 | remainder_Assets | 9,577,000 |
| 4 | LiabilitiesCurrent | 45,420,000 |
| 5 | LiabilitiesNoncurrent | 894,000 |
| 6 | remainder_Liabilities | 126,653,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 111,514,105 |
| 9 | ResearchAndDevelopmentExpense | 37,267,391 |
| 10 | remainder_Expenses | 28,420,834 |
| 11 | remainder_Revenues | 203,481,660 |
| 12 | remainder_NetIncome | -112,032,407 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 158,872,000 |
| 1 | Liabilities | 172,967,000 |
| 2 | Expenses | 177,202,330 |
| 3 | Revenues | 203,481,660 |
| 4 | StockholdersEquity | -14,095,000 |
| 5 | NetIncome | -85,753,077 |
| 6 | ComprehensiveNetIncome | -85,753,077 |
| 7 | BaseVar | 412,277,698 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -0.702 |
| 9 | EconomicCapitalRatio | 1.36 |
Edgar->Model Mapping
Feature Distribution
Change over Time
